Clinical Trial

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-27; most recent amendment 2026-05-28.
Trial Details
NCT Number NCT06798896
Lead Sponsor Supernus Pharmaceuticals, Inc.
Conditions Focal Onset Seizures
Enrollment 216 participants
Start Date 2024-12-30
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-01